How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody.

How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody.

Publication date: Oct 12, 2024

Paramyxoviruses including measles, Nipah, and parainfluenza viruses are public health threats with pandemic potential. Human parainfluenza virus type 3 (HPIV3) is a leading cause of illness in pediatric, older, and immunocompromised populations. There are no approved vaccines or therapeutics for HPIV3. Neutralizing monoclonal antibodies (mAbs) that target viral fusion are a potential strategy for mitigating paramyxovirus infection, however their utility may be curtailed by viral evolution that leads to resistance. Paramyxoviruses enter cells by fusing with the cell membrane in a process mediated by a complex consisting of a receptor binding protein (HN) and a fusion protein (F). Existing atomic resolution structures fail to reveal physiologically relevant interactions during viral entry. We present cryo-ET structures of pre-fusion HN-F complexes in situ on surfaces of virions that evolved resistance to an anti-HPIV3 F neutralizing mAb. Single mutations in F abolish mAb binding and neutralization. In these complexes, the HN protein that normally restrains F triggering has shifted to uncap the F apex. These complexes are more readily triggered to fuse. These structures shed light on the adaptability of the pre-fusion HN-F complex and mechanisms of paramyxoviral resistance to mAbs, and help define potential barriers to resistance for the design of mAbs.

Open Access PDF

Concepts Keywords
Abolish Animals
Atomic Antibodies, Monoclonal
Paramyxoviruses Antibodies, Monoclonal
Therapeutics Antibodies, Neutralizing
Viral Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
Cryoelectron Microscopy
HN Protein
HN Protein
Humans
Models, Molecular
Mutation
Parainfluenza Virus 3, Human
Viral Fusion Proteins
Viral Fusion Proteins
Virus Internalization

Semantics

Type Source Name
disease MESH measles
pathway KEGG Measles
disease MESH parainfluenza
disease MESH infection
disease IDO process
disease IDO protein
disease MESH pneumonia
drug DRUGBANK Esomeprazole
drug DRUGBANK Coenzyme M
drug DRUGBANK L-Cysteine
disease MESH influenza
disease IDO blood
disease IDO assay
disease IDO site
disease IDO infectivity
drug DRUGBANK Piroxicam
disease IDO cell
drug DRUGBANK Medical air
disease IDO production
disease MESH croup
disease MESH bronchiolitis
disease MESH respiratory infections
disease MESH complications
disease IDO host
disease MESH long term infection
drug DRUGBANK Streptomycin
drug DRUGBANK Cefaclor
drug DRUGBANK Zanamivir
drug DRUGBANK Methylergometrine
drug DRUGBANK Cholesterol
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Water
drug DRUGBANK Ammonium chloride
drug DRUGBANK Potassium
drug DRUGBANK Magnesium
drug DRUGBANK Calcium
disease IDO quality
drug DRUGBANK Biotin
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Tromethamine
drug DRUGBANK Glycine
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Activated charcoal
drug DRUGBANK Gold
drug DRUGBANK Oxygen
drug DRUGBANK Titanium
pathway REACTOME Reproduction
disease MESH respiratory syncytial virus infections
disease MESH Cancer
disease MESH virus infections
disease MESH hematologic malignancy
drug DRUGBANK Palivizumab
drug DRUGBANK Diethylstilbestrol
disease MESH Nipah virus infection

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *